Hepatitis C Virus
Nabi initiates phase 2 proof-of-concept trial of Civacir in HCV-related liver disease
Published in Hepatitis Weekly, February 19th, 2007
Nabi Biopharmaceuticals (NABI) announced that it has initiated its phase 2 proof-of-concept clinical trial for Civacir [hepatitis C immune globulin (human)]. Civacir, the company's plasma-derived, polyclonal antibody product candidate, if approved, would be the first therapy for the prevention of the recurrence of hepatitis C-related liver disease in hepatitis C virus (HCV) positive liver transplant recipients, or in patients who received an HCV-positive liver. Currently, there are no marketed therapies specifically indicated for prevention of re-infection post-liver transplant in HCV-positive patients.
Nabi Biopharmaceuticals is co-developing Civacir with Kedrion...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2007-02-19)
More Articles from Hepatitis Weekly
- Cancer Gene Therapy
Research from University of Thessaly, Department of Biology has provided new information about cancer gene therapy - Cancer Vaccines
Data on cancer vaccines published by researchers at University of Cologne, Institute of Virology - Hepatitic B Vaccines
Research on hepatitic b vaccines published by scientists at Tehran University of Medical Sciences, Department of Gastroenterology - Hepatitic B Vaccines
Studies from Ataturk Education and Training Hospital describe new findings in hepatitic b vaccines - Hepatitis A Vaccines
Medical University of Vienna details research in hepatitis a vaccines - Hepatitis A Virus Therapy
Research from Hannover Medical School broadens understanding of hepatitis A virus therapy - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
